Amniotic Fluid-Derived Mesenchymal Stem Cells Prevent Fibrosis and Preserve Renal Function in a Preclinical Porcine Model of Kidney Transplantation

Baulier, Edouard; Favreau, Fréderic; Corf, Amélie Le; Jayle, Christophe; Schneider, Fabrice; Goujon, Jean-Michel; Féraud, Olivier; Bennaceur-Griscelli, Annelise; Hauet, Thierry; Turhan, Ali G.

doi:10.5966/sctm.2013-0186

Cited by 66 publications

(42 citation statements)

References 42 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, in vitro investigations revealed that the two cell types produced different cytokines and growth factors, suggesting that their therapeutic activities are governed by different mediators. A recent study reaffirmed their therapeutic capacities in porcine models of autotransplantation [58]. The investigators found that injected autologous AFDSCs improved glomerular and tubular functions and abrogated fibrosis development at 3 months.…”

Section: Amniotic Fluid-derived Stem Cellsmentioning

confidence: 87%

Tissue-Engineering Approaches to Restore Kidney Function

et al. 2015

View full text Add to dashboard Cite

Kidney transplantation for the treatment of chronic kidney disease has established outcome and quality of life. However, its implementation is severely limited by a chronic shortage of donor organs; consequently, most candidates remain on dialysis and on the waiting list while accruing further morbidity and mortality. Furthermore, those patients that do receive kidney transplants are committed to a life-long regimen of immunosuppressive drugs that also carry significant adverse risk profiles. The disciplines of tissue engineering and regenerative medicine have the potential to produce alternative therapies which circumvent the obstacles posed by organ shortage and immunorejection. This review paper describes some of the most promising tissue-engineering solutions currently under investigation for the treatment of acute and chronic kidney diseases. The various stem cell therapies, whole embryo transplantation, and bioengineering with ECM scaffolds are outlined and summarized.

show abstract

Section: Amniotic Fluid-derived Stem Cellsmentioning

confidence: 87%

Tissue-Engineering Approaches to Restore Kidney Function

et al. 2015

View full text Add to dashboard Cite

show abstract

“…We demonstrated that stem cells derived from amniotic fluid are renoprotective in animal models of glycerol‐induced AKI, as well as CKD . AFSC seem to protect tubular and glomerular cells by stimulating endogenous repair mechanisms, thus reducing inflammation and fibrosis .…”

Section: Different Types Of Stem Cells and Preclinical Models Of Renamentioning

confidence: 88%

Concise Reviews: Stem Cells and Kidney Regeneration: An Update

Marcheque

Bussolati

Csete

et al. 2018

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Significant progress has been made to advance stem cell products as potential therapies for kidney diseases: various kinds of stem cells can restore renal function in preclinical models of acute and chronic kidney injury. Nonetheless this literature contains contradictory results, and for this reason, we focus this review on reasons for apparent discrepancies in the literature, because they contribute to difficulty in translating renal regenerative therapies. Differences in methodologies used to derive and culture stem cells, even those from the same source, in addition to the lack of standardized renal disease animal models (both acute and chronic), are important considerations underlying contradictory results in the literature. We propose that harmonized rigorous protocols for characterization, handling, and delivery of stem cells in vivo could significantly advance the field, and present details of some suggested approaches to foster translation in the field of renal regeneration. Our goal is to encourage coordination of methodologies (standardization) and long‐lasting collaborations to improve protocols and models to lead to reproducible, interpretable, high‐quality preclinical data. This approach will certainly increase our chance to 1 day offer stem cell therapeutic options for patients with all‐too‐common renal diseases. Stem Cells Translational Medicine 2019;8:82–92

show abstract

“…Other efforts at marginal organ rehabilitation in the setting of NMP have utilized mesenchymal stem cells (MSCs) for their regenerative and anti-inflammatory properties [65].…”

Section: Mesenchymal Stem Cell Therapymentioning

confidence: 99%